Aktuellt
SENASTE
Once again, Fluoguide has managed to turn out a positive top line result in a clinical trial, this time in lung cancer, in which 73% of patients' cancers were illuminated by FG001, with continued a clean safety/tolerability profile and similar pharmacokinetics to that seen in glioma. In our view, this is a promising start to the lung cancer programme and a de-risking event, albeit perhaps not to the same extent as for the earlier glioma and interim head and neck data.
LÄS MER
